The Wistar Institute
3601 Spruce Street
45 articles with The Wistar Institute
The Wistar Institute and Batavia Biosciences Launch Collaboration to Manufacture and Distribute Wistar’s Rubella Vaccine Globally
The Bill & Melinda Gates Foundation supports international collaboration to expand global access to life-saving vaccines
Boston Biomedical announced it had launched an oncology research alliance with Columbia University, Harvard University and The Wistar Institute.
Integral Molecular Selected as the First Industry Partner in The Wistar Institute's Biomedical Research Technician Apprenticeship
Integral Molecular, Inc. has been selected by The Wistar Institute, a global leader in cancer, immunology and infectious disease research as the first industry partner for its Biomedical Research Technician Apprenticeship.
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection
Inovio Pharmaceuticals, Inc. announced that the company and its collaborator The Wistar Institute have received a $4.6 million National Institutes of Health grant in support of innovative research to tackle antimicrobial resistance employing Inovio's DNA-encoded monoclonal antibodies platform.
IMV Announces Research Collaboration with The Wistar Institute to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation
IMV Inc. announced a collaboration with The Wistar Institute and Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and Cellular Oncogenesis Program and director of Wistar’s Melanoma Research Center.
Anixa Biosciences Extends Collaborative Research Agreement with The Wistar Institute and Leading Myeloid-derived Suppressor Cell Researcher Dmitry I. Gabrilovich, M.D., Ph.D.
Anixa Biosciences, Inc. announced it has extended its collaboration with The Wistar Institute and Dmitry I. Gabrilovich, M.D., Ph.D. Gabrilovich is a pioneer in the field of myeloid-derived suppressor cell (MDSC) biology and its roles in cancer progression and therapy response.
First-in-class small molecule targeting EBV-driven cancers to enter Phase 1 in 2019
Harbour BioMed and The Wistar Institute Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases
Harbour BioMed and The Wistar Institute announced that they have entered into a multi-year, multifaceted research collaboration to co-discover novel antibodies for the treatment of cancer and infectious diseases.
Innate Biologics, LLC Enters Into Collaboration Agreement With The Wistar Institute to Develop Anti-Inflammatory Protein Platform
Innate Biologics has entered into a collaborative research agreement with The Wistar Institute, an international leader in biomedical research.
Inovio and The Wistar Institute Receive More Than $4.6M in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria
The grants were from the Bill & Melinda Gates Foundation and the (NIH.
Science Center's QED Program Awards $600,000 to Advance the Commercialization of Three University Technologies Awards Given to New Jersey Institute of Technology, Temple University and The Wistar Institute
The awardees were selected from a pool of 54 applicants from 12 academic and research institutions in Pennsylvania, New Jersey and Delaware.
The Wistar Institute And BioTime Subsidiary OncoCyte Corporation Expand Agreement To Develop Molecular Diagnostic Test For The Detection Of Lung Cancer
BioTime Release: OncoCyte Corporation’s Collaborators At The Wistar Institute Present Positive Clinical Interim Results Of Blood-Based Diagnostic Test For Non-Invasive Detection Of Lung Cancer
BioTime’s Subsidiary OncoCyte Corporation Announces Completion Of Multi-Site Clinical Study Of Lung Cancer Diagnostic By Collaborators At The Wistar Institute
BioTime’s Subsidiary OncoCyte Corporation and The Wistar Institute to Collaboratively Develop Cancer Diagnostics
ReCyte Therapeutics and OncoCyte Corporation Release: BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming from The Wistar Institute